Ratings UnitedHealth Group Incorporated Sao Paulo

Equities

UNHH34

BRUNHHBDR000

Delayed Sao Paulo Other stock markets 14:25:48 2024-05-15 EDT			5-day change	1st Jan Change
38.04 ^BRL	+4.11%		+3.68%	+5.11%

05-10	Stephens Adjusts Price Target on UnitedHealth to $565 From $545	MT
05-08	Ascension warns of suspected cyberattack; clinical operations disrupted	RE

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Analyst opinion has improved significantly over the past four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The firm trades with high earnings multiples: 28.34 times its 2024 earnings per share.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Managed Healthcare

	1st Jan change	Capi.	ESG Refinitiv
UNITEDHEALTH GROUP INCORPORATED	+5.11%	473B	-
ELEVANCE HEALTH, INC.	+14.47%	124B	A-
CIGNA	+14.57%	98.41B	B-
HUMANA INC.	-24.89%	41.51B	A-
CENTENE CORPORATION	+4.96%	41.02B	B-
MOLINA HEALTHCARE, INC.	-3.80%	20.51B	B-
PROGYNY, INC.	-27.33%	2.62B	C+
ALIGNMENT HEALTHCARE, INC.	-17.60%	1.34B	B-
CLOVER HEALTH INVESTMENTS, CORP.	+0.75%	506M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes